Effectiveness of a combined strategy to improve therapeutic compliance and degree of control among patients with hypercholesterolaemia: a randomised clinical trial

BMC Cardiovascular Disorders

José J Pérez-Pascual⁹  Maria Candelaria Ayuso-Raya⁹  José M del Campo-del Campo³  Susana Morena-Rayo⁵  José M Ferreras-Amez⁴  Mariano Blasco-Valle⁶  Alejandro Villena-Ferrer¹  Francisco Escobar-Rabadán⁹  Juan M Téllez-Lapeira⁸  Fernando Lago-Deibe²  Joseba Rabanales-Sotos^1,10  Ignacio Párraga-Martínez⁷ 

[1] San Clemente Health Centre, Health Care Service of Castilla-La Mancha, C/Ancha s/n, 16600 Cuenca, San Clemente, Spain;Sárdoma Health Centre, Health Care Service of Galicia, C/Baixada a Laxe 76, 36214 Vigo, Spain;Almansa Health Centre, Health Care Service of Castilla-La Mancha, C/San Juan s/n, 02640 Albacete, Almansa, Spain;Royo Villanova Hospital, Health Care Service of Aragón, C/San Gregorio 30, 50015 Zaragoza, Spain;Hellín 2 Health Centre, Health Care Service of Castilla-La Mancha, C/Turbas de Cuenca 15, 02400 Albacete, Hellín, Spain;Delicias Sur Health Centre, Health Care Service of Aragón, C/Manuel Dronda 1, 50009 Zaragoza, Spain;La Roda Health Centre, Health Care Service of Castilla-La Mancha, C/Mártires 63, 02630 Albacete, La Roda, Spain;Albacete Area Vb Health Centre, Health Care Service of Castilla-La Mancha, C/Profesor Macedonio Jiménez s/n, 02006 Albacete, Spain;Albacete Area IV Health Centre, Health Care Service of Castilla-La Mancha, C/Seminario 4, 02006 Albacete, Spain;Cuenca Faculty of Nursing, University of Castilla-La Mancha, C/Camino de Pozuelo s/n, 16071 Cuenca, Spain

关键词: Primary health care;    Medication adherence;    Hypercholesterolaemia;   

Others  :  1103128
DOI  :  10.1186/1471-2261-15-8

 received in 2014-12-14, accepted in 2015-01-13,  发布年份 2015

【 摘 要 】

Background

In subjects with hypercholesterolaemia, cholesterol values remain above guideline levels. One of the limiting factors to the achievement of goals in such patients is therapeutic non-adherence. The aim of this study is to assess the effectiveness of an intervention designed to improve control of hypercholesterolaemic patients, consisting of a combined strategy that would include the delivery of printed information, treatment-compliance check cards and the dispatch of text messages as complementary measures in support of the intervention at the general practitioner’s practice.

Methods/Design

A randomised, parallel-group clinical trial will be conducted at the family medicine outpatient facilities of eight health centres in three of Spain’s Autonomous Regions (Comunidades Autónomas), covering a total of 358 subjects aged 18 years or over with diagnosis of hypercholesterolaemia. Patients in the intervention group will be supplied with printed material with information on the disease and its management, mobile-telephone text messages with guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance, and self-report cards to check compliance with recommendations. Both groups -intervention and control- will receive routine recommendations from their physicians in accordance with current European clinical practice guidelines for hypercholesterolaemia and cardiovascular risk management. As regards the measurements to be made, the main variable is the proportion of subjects who attain the low density lipoprotein cholesterol levels set as a target across a follow-up period of 24 months. The secondary variables are as follows: adherence to recommendations on lifestyle and adherence to drug treatment; variation in lipid profiles and cardiovascular risk levels; appearance of cardiovascular events; physical activity; food consumption; smoking habit; anthropometric measures; blood pressure; health problems; use of hypolipidaemic agents; socio-demographic data; beliefs and expectations about preventive recommendations; and degree of satisfaction with the combined strategy.

Discussion

Should this intervention prove effective, a recommendation could be issued on the application of this combined strategy to subjects with hypercholesterolaemia. It is a simple, relatively inexpensive intervention.

Trial registration

ClinicalTrials.gov: NCT02314663.

【 授权许可】

   
2015 Párraga-Martínez et al.; licensee BioMed Central.

【 参考文献 】

• [1]Medrano MJ, Cerrato E, Boix R, Delgado-Rodriguez M: Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies. Med Clin (Bar) 2005, 124:606-12.
• [2]Gabriel R, Alonso M, Segura A, Tormo MJ, Artigao LM, Banegas JR, et al.: Prevalence, geographic distribution and geographic variability of major cardiovascular risk factors in Spain. Pooled analysis of data from population-based epidemiological studies: the ERICE Study. Rev Esp Cardiol 2008, 61:1030-40.
• [3]Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al.: European guidelines on cardiovascular disease prevention in clinical practice: force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 28:2375-414.
• [4]Marrugat J, Solanas P, D’Agostino R, Sullivan I, Ordovas J, Cordón F, et al.: Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol 2003, 56:253-61.
• [5]Lobos JM, Royo-bordonada M, Brotons C, Álvarez-Sala L, Armario P, Maiques A, et al.: Guía Europea de prevención cardiovascular en la práctica clínica: adaptación española del CEIPC 2008. Rev Esp Salud Pública 2008, 82:581-616.
• [6]National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report report of the National Cholesterol Education Program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002, 106:3143-421.
• [7]Reiner Z, Catapano A, De Backer C, Graham I, Taskinen M, Wiklund O, et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-818.
• [8]Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al.: Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-40.
• [9]Vegazo O, Banegas JR, Civeira F, Serrano Aisa P, Jiménez FJ, Luengo E, et al.: Prevalence of dyslipidemia in outpatients of the Spanish health service: the HISPALIPID Study. Med Clin (Barc) 2006, 127:331-4.
• [10]Alvarez-Sala LA, Suárez C, Mantilla T, Franch J, Ruilope LM, Banegas JR, et al.: PREVENCAT study: control of cardiovascular risk in primary care. Med Clin (Barc) 2005, 124:406-10.
• [11]Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al.: EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009, 16:121-37.
• [12]Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, et al.: Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
• [13]Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, et al.: Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008, 371:1999-2012.
• [14]Reiner Z, Sonicki Z, Tedeschi-Reiner E: Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev Med 2010, 51:494-6.
• [15]Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455-61.
• [16]Bermingham M, Hayden J, Dawkins I, Miwa S, Gibson D, McDonald K, et al.: Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther 2011, 33(9):1180-9.
• [17]World Health Organization: Adherence to long term therapies: evidence for action. Geneva; 2003. [http://apps.who.int/medicinedocs/en/d/Js4883e/ webcite]
• [18]Bueno M, Barrionuevo MD, Fikri N, García-Jiménez E: Causes of non-compliance of patients who attend a community pharmacy in Granada. Aten Primaria 2008, 40:101-6.
• [19]Gil-Guillén V, Merino-Sánchez J, Sánchez-Ruiz T, Amorós-Barber T, Aznar-Vicente J, Abellán-Alemán J, et al.: Valoración del riesgo cardiovascular en la fase transversal del estudio Mediterránea. Rev Clin Esp 2009, 209:211-20.
• [20]Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al.: Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011, 32(17):2143-52.
• [21]Márquez E, Casado JJ, Corchado Y, Chaves R, Grancío A, Losada C, et al.: Eficacia de una intervención para mejorar el cumplimiento terapéutico en las dislipemias. Aten Primaria 2004, 33(8):443-50.
• [22]Márquez E, Gil V, Casado JJ, Martel N, de la Figuera M, Martin JL, et al.: Análisis de estudios publicados sobre el incumplimiento terapéutico en el tratamiento de la hipertensión arterial en España entre los años 1984–2005. Aten Primaria 2006, 38:325-32.
• [23]Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA: Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 1991, 13:489-95.
• [24]Palop V, Martínez I: Adherencia al tratamiento en el paciente anciano. Inf Ter Sist Nac Salud 2004, 28:113-20.
• [25]McDonald P, Garg AX, Haynes RB: Intervention to enhance patient adherente to medication prescriptions (SR). JAMA 2002, 288:2868-79.
• [26]Gibbs S, Waters WE, George CF: The beneficits of prescription information leaflets. Br J Clin Pharmacol 1989, 27:723-73.
• [27]Baker D, Roberts DE, Newcombe RG, Fox KA: Evaluation of drug information for cardiology patients. Br J Clin Pharmacol 1991, 31:525-31.
• [28]Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M: Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacoterapy 1999, 19:860-9.
• [29]Erickson SR, Slaughter R, Halapy H: Pharmacists’ ability to influence outcomes of hypertension therapy. Pharmacotherapy 1997, 17:140-7.
• [30]Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE: Impact of pharmacy counseling on compliance and effectiveness of combination lipidlowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000, 20:410-6.
• [31]Bodiya A, Vorias D, Dickson HA: Does telephone contac with a physicians’s office staff improve mammogram screening rates? Fam Med 1999, 31:324-6.
• [32]Batalla C: Comentario: una herramienta más para mejorar el cumplimiento terapéutico. Aten Primaria 2009, 41:191-2.
• [33]Haynes RB, McKibbon KA, Kanani R, Brouwers C, Oliver T: Interventions to assist patients to follow prescriptions for medications. In Cochrane collaboration: cochrane library. Oxford: Update Software; 1998.